Vertex Pharmaceuticals, Inc [VRTX] stock is trading at $404.21, up 3.21%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VRTX shares have gain 7.33% over the last week, with a monthly amount glided 0.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] stock has seen the most recent analyst activity on September 25, 2025, when Leerink Partners upgraded its rating to an Outperform but kept the price target unchanged to $456 for it. On August 06, 2025, upgrade upgraded it’s rating to Overweight but maintained its price target of $460 on the stock. Wolfe Research downgraded its rating to a Peer Perform. Leerink Partners downgraded its rating to a Market Perform but $503 remained the price target by the analyst firm on May 06, 2025. In a note dated February 12, 2025, Canaccord Genuity upgraded an Hold rating on this stock and boosted its target price from $408 to $424.
Vertex Pharmaceuticals, Inc [VRTX] stock has fluctuated between $362.50 and $519.88 over the past year. Currently, Wall Street analysts expect the stock to reach $479.8 within the next 12 months. Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] shares were valued at $404.21 at the most recent close of the market. An investor can expect a potential return of 18.7% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] reported sales of 11.39B for the trailing twelve months, which represents a growth of 13.33%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at 0.34%, Pretax Profit Margin comes in at 0.38%, and Net Profit Margin reading is 0.32%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.22 and Total Capital is 0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 395.30 points at the first support level, and at 386.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 410.31, and for the 2nd resistance point, it is at 416.41.
Ratios To Look Out For
For context, Vertex Pharmaceuticals, Inc’s Current Ratio is 2.52. As well, the Quick Ratio is 2.16, while the Cash Ratio is 1.2. Considering the valuation of this stock, the price to sales ratio is 9.10, the price to book ratio is 6.03 and price to earnings (TTM) ratio is 28.89.
Transactions by insiders
Recent insider trading involved Bhatia Sangeeta N., Director, that happened on Aug 27 ’25 when 266.0 shares were sold. Director, Bhatia Sangeeta N. completed a deal on Aug 27 ’25 to buy 266.0 shares. Meanwhile, CEO & President Kewalramani Reshma bought 10000.0 shares on Aug 06 ’25.